

# Franck Morin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5989275/publications.pdf>

Version: 2024-02-01

23  
papers

2,455  
citations

623734

14  
h-index

677142

22  
g-index

23  
all docs

23  
docs citations

23  
times ranked

3432  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 719-728.	1.6	37
2	Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. <i>European Journal of Cancer</i> , 2022, 166, 51-59.	2.8	14
3	Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial. <i>Lung Cancer</i> , 2021, 164, 84-90.	2.0	0
4	Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. <i>Lung Cancer</i> , 2020, 140, 19-26.	2.0	16
5	Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial. <i>European Journal of Cancer</i> , 2020, 138, 193-201.	2.8	4
6	Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab. <i>Journal of Clinical Medicine</i> , 2020, 9, 3861.	2.4	23
7	Development and Validation of a Simplified Prognostic Score in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100016.	1.1	6
8	Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100052.	1.1	9
9	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. <i>European Journal of Cancer</i> , 2020, 131, 27-36.	2.8	44
10	Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). <i>Clinical Lung Cancer</i> , 2019, 20, 222-230.	2.6	3
11	Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. <i>European Journal of Cancer</i> , 2019, 116, 86-97.	2.8	18
12	A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 903-913.	1.1	132
13	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. <i>Clinical Lung Cancer</i> , 2019, 20, e564-e575.	2.6	49
14	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 239-253.	10.7	342
15	Cost-effectiveness of <i>KRAS</i> , <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. <i>European Respiratory Journal</i> , 2018, 51, 1701467.	6.7	16
16	Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times. <i>European Respiratory Journal</i> , 2018, 51, 1800844.	6.7	1
17	Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of) <i>TJ ETQq1 1 0.784314 rgBT /Overlock</i>		
18	Association between lung cancer somatic mutations and occupational exposure in never-smokers. <i>European Respiratory Journal</i> , 2017, 50, 1700716.	6.7	16

#	ARTICLE	IF	CITATIONS
19	Overall survival with crizotinib and next-generation ALK inhibitors in <i>ALK</i> -positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. <i>Oncotarget</i> , 2017, 8, 21903-21917.	1.8	140
20	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). <i>Lancet, The</i> , 2016, 387, 1415-1426.	13.7	790
21	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 1405-1414.	13.7	753
22	A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non-Small Cell Lung Cancer Setting—IFCT/ERMETIC2 Project Part 1. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 45-55.	2.8	31
23	Second-line therapy in elderly patients with advanced nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2014, 43, 240-249.	6.7	10